Novel Potent EGFR-JAK3 Dual-Target Inhibitor that Overcomes KRAS Mutation Resistance in Colorectal Cancer.

Anti-cancer agents in medicinal chemistry（2023）

引用 0|浏览19

暂无评分

摘要

In summary, this study provides an important structural basis and mechanistic study for future effective treatment of colorectal cancer.

查看译文

关键词

EGFR,JAK3,KRAS mutation,clinical research,colorectal cancer,dual-target inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要